10-Q · August 14, 2026
Q1 2026 operating metrics improved substantially: revenue was $7.0 million, gross margin was 99.8% and operating margin was 49.5%, versus revenue of $5,065, gross margin of 20.0% and operating margin of negative…
Earnings analysis · 10-Q
HCWB earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
HCW Biologics generated substantial year-over-year revenue growth to $135,568 from $6,550, and its operating loss narrowed to $3.2 million. However, the company reported a $15.4 million loss attributable to common…
Read full summary
HCW Biologics generated substantial year-over-year revenue growth to $135,568 from $6,550, and its operating loss narrowed to $3.2 million. However, the company reported a $15.4 million loss attributable to common stockholders, or negative $11.58 per diluted share, and had only $741,324 of cash, cash equivalents and market investments against significant legal and operating obligations. Unremediated material weaknesses, potential financing dilution and ongoing Nasdaq monitoring further weigh on the outlook. The filing states that there were no material changes to the risk factors disclosed in the Annual Report.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-11.58
What stood out
-
License activity drove revenue growth
Revenue increased to $135,568 from $6,550 in the year-ago quarter, a $129,018 increase or approximately 1,970%, driven by license activity.
-
Operating loss narrowed
The operating loss narrowed to $3.2 million, indicating improvement in operating performance despite the company remaining loss-making.
-
Clinical milestones remain on track
HCW9302 remains on track for a full Phase 1 readout in Q4 2026, while the HCW11-018b trial is expected to begin in the first half of 2027 subject to FDA authorization.
-
Cash and investments totaled $741,324
The company reported $741,324 of cash, cash equivalents and market investments as of June 30, 2026, providing a quantified liquidity resource.
-
Nasdaq bid-price compliance regained
HCW Biologics regained compliance with Nasdaq's Bid Price Rule on June 29, 2026, subject to remaining terms through September 22, 2026.
What to watch
-
Severe liquidity pressure
Cash, cash equivalents and market investments were only $741,324 at June 30, 2026, while the company reported a $5.4 million liability for remaining legal fees and $2.2 million owed to BE&K and other lien holders.
-
Warrant accounting increased net loss
Net loss attributable to common stockholders was $15.4 million, or $11.58 per diluted share, including a $2.4 million warrant-liability loss; this materially exceeded the $3.2 million operating loss.
-
Unremediated material weaknesses
Management concluded disclosure controls and procedures were ineffective and that internal control over financial reporting was not effective as of June 30, 2026. Previously identified weaknesses included a $1.5 million long-lived-asset impairment adjustment and an ASC 260 error requiring restatement of March 31, 2026 financial statements.
-
Financing creates dilution
The company completed a July 29, 2026 private placement of 618,682 units for approximately $1.6 million before expenses, with additional warrants subject to stockholder approval, creating potential dilution.
-
Nasdaq delisting remains possible
Nasdaq monitoring remains a listing risk: the mandatory panel monitor runs through June 17, 2027, and a new Bid Price Rule deficiency during the monitoring period could result in a delisting determination without an additional cure period.
-
Construction litigation and obligations
The company faces a five-day jury trial in December 2026 in the BE&K matter, with $2.2 million remaining owed to BE&K and other lien holders as of June 30, 2026.
Management's outlook
No quantitative revenue or EPS guidance was provided. Management stated it remains on track for a full HCW9302 Phase 1 readout in Q4 2026 and expects the HCW11-018b trial to begin in the first half of 2027, subject to FDA authorization.
Earlier filings 4
10-Q · May 14, 2026
HCW Biologics reported revenues of $6.5 million for Q4 2026, a substantial increase from $5,065 in Q4 2025, driven by the closure of the Trimmune Licensing deal. The diluted EPS, however, remains at -$1.97, indicating…
10-K · March 31, 2026
HCW Biologics is a clinical‑stage immunotherapeutics company with a large preclinical pipeline (>50 molecules) and active first‑in‑human work (HCW9302). Commercial‑ready reagent products (HCW9201, HCW9206) and recent…
10-Q · November 14, 2025
HCW Biologics reported Q3 2025 revenue of $15,606 (vs. $426,423 in Q3 2024) and a GAAP net loss of $4,554,336, or $(2.02) per share (improved from $(4.13) in Q3 2024). Cash fell to $1,096,909 at September 30, 2025 and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.